Company Announcement no. 10/2013
To: NASDAQ OMX Copenhagen A/S Hørsholm, Denmark, 1 May 2013
New Articles of Association
Hørsholm, 1 May 2013 – Veloxis Pharmaceuticals A/S (OMX: VELO), has today registered revised articles of association with the Danish Business Authority in continuation of the company's annual general meeting held on 17 April 2013.
The new articles of association is attached.
For more information, please contact:
Veloxis Pharmaceuticals A/S
Bill Polvino Johnny Stilou
President & CEO EVP, Chief Financial Officer
Mobile: +1 917 647 9107 Mobile: +45 21 227 227
Email: wjp@veloxis.com Email: jst@veloxis.com
About Veloxis Pharmaceuticals
Based in Hørsholm, Denmark, with an office in New Jersey, Veloxis is a specialty pharmaceutical company. The company's lead product candidate is LCP-Tacro for immunosuppression, specifically organ transplantation. Veloxis' unique, patented delivery technology, MeltDose®, can improve absorption and bioavailability at low scale up costs. Veloxis has a lipid lowering product, Fenoglide®, currently on the U.S. market that is commercialized through partner Santarus, Inc. Veloxis is listed on the NASDAQ OMX Copenhagen under the trading symbol OMX: VELO.
For further information, please visit www.veloxis.com.
